Bladder Cancer Therapeutics Market

Bladder Cancer Therapeutics Market Size (2022 to 2027)

The size of the global bladder cancer therapeutics market is expected to grow to USD 321.00 million by 2027 from USD 252.11 million in 2022, growing at a CAGR of 4.95% during the forecast period.

Bladder cancer is the uncontrolled growth of abnormal cells in the urinary bladder lining with the epithelial cells. These cells even spread through the lining into the bladder's muscular wall. Several therapies have currently evolved to treat bladder cancer; thus, it builds a higher demand for bladder cancer therapeutics. The cancerous tissue is known as tumors and can spread to other nearby cells and tissues if not treated at the earliest stage. Urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others are bladder cancer treatments. According to the American cancer society, 81,400 new cancer cases were registered in 2020. It was estimated that 62,100 were men and 19,300 were women cancer patients. In 2019, the CANADA center for drug research and development announced USD 1.2 million investment in Sitka biopharma. The development activities for clinical trials named STK-01 are used to treat bladder cancer nanotechnology. 

MARKET DRIVERS:

The increasing incidence of tumors, innovations in drugs for treatment, and technological advances are propelling the growth of the global bladder cancer therapeutics market.

As this cancer is more common in adults over 50 years, the increase in the geriatric population also contributes to the market's growth. Furthermore, government initiatives increased awareness of bladder cancer, and available treatments and progressive health services associated with increased spending on health care also boost the global bladder cancer therapeutics market. Since cancer is an asymptomatic disease in the initial stage, it requires an accurate diagnosis at an early stage.

Technological advancements, new treatments, advanced healthcare services, increasing knowledge about bladder cancer therapies among the people, the launch of new novel drugs, the acceptance of effective diagnostic tools, and the rise in healthcare expenditure are the factors that drive the global bladder cancer therapeutics market growth. In addition, the launch of new products, rise in investments in research and development, and the manufacturing demand increases pose differentiable growth opportunities in the global bladder cancer therapeutics market.

MARKET RESTRAINTS:

Factors such as less availability of various treatment options, an increase in healthcare services, and increasing knowledge about all kinds of cancers are the facts that are hindering the global bladder cancer therapeutics market growth. Furthermore, high costs associated with the devices may hamper the growth. In addition, strict regulatory policies, poorly developed healthcare infrastructure, and limited adoption of advanced cancer therapies hinder the growth. People in rural areas are less aware of the treatment procedures available, and less availability of skilled persons in diagnostic centers is a significant challenge for the bladder cancer therapeutics market.

Impact of COVID-19 on the global bladder cancer therapeutics market:

The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) has affected many individuals and healthcare systems. The primary concern is associated with the difficulty in engaging with healthcare systems. Bladder cancer majorly occurs in the elderly population. The global economy and the market were adversely affected; the market structure has been completely changed. Countries are in an international run to expand and produce a vaccine for the SARS-COV-2. Government bodies are increasing funding for vaccine development. A nationwide lockdown had been implemented due to a surge in the covid-19 cases. The concerning activities on bladder cancer therapeutics had stopped and been postponed. 

The market expects significant growth despite the negative impact during the forecast period. Several new bladder cancer cases have been registered in the recent period through which market expansion can be possible. In addition, different cancer therapies, such as immunotherapies in cancer treatment, are recharged among the people. It recently developed treatment modalities that are conventional therapeutic options in bladder cancer management. However, the market is anticipated to witness a healthy growth rate during the forecast period.

REPORT COVERAGE:

This research report on the global bladder cancer therapeutics market has been segmented and sub-segmented based on type, treatment, and region.

Bladder Cancer Therapeutics Market - By Type:

• Transitional Cell Bladder Cancer
• Non-Muscle Invasive/Superficial Bladder Cancer
• Invasive Bladder Cancer
• Squamous Cell Bladder Cancer
• Adenocarcinoma of the Bladder
• Rare Bladder Cancers

Based on the type, the transitional cell bladder segment held the largest share of the global bladder cancer therapeutics market in 2021 due to improving healthcare infrastructures in developed and developing countries.

The superficial bladder cancer segment is expected to grow at a brisk pace in the global bladder cancer therapeutics market during the forecast period, and the growth of this segment is attributed to improving healthcare infrastructures in developed and developing countries, rising awareness about the superficial bladder, and technological advancements.

Bladder Cancer Therapeutics Market - By Treatment:

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Intravesical Therapy

Based on the treatment type, the chemotherapy segment held the highest share due to the many chemotherapy drugs in 2020. On the other hand, the immunotherapy segment is predicted to showcase a healthy growth rate in the global bladder cancer therapeutics market. The immunotherapy segment growth is majorly driven by the increasing prevalence of targeted diseases, growing adoption of immunotherapy over conventional treatments, and rising demand for monoclonal antibodies and biosimilars.

Bladder Cancer Therapeutics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American bladder cancer therapeutics market accounted for 41.0% of the global market in 2021. In contrast, Asia-Pacific is expected to grow at the highest CAGR of 5.68% from 2022 to 2027. Therefore, North America is predicted to lead the market for bladder cancer therapeutics during the forecast period. Most of the region is attributed to increased bladder cancer incidence, innovative healthcare solutions, advanced healthcare infrastructure, and growing concern about bladder problems.

The Europe bladder cancer therapeutics market represented the second-largest share of the global market in 2021.

The bladder cancer therapeutics market in Asia-Pacific is expected to experience substantial growth. This increase is mainly due to the growing awareness of bladder diseases and innovative diagnostic and treatment options. As a result, the leading market players believe that Asian countries are lucrative markets for bladder cancer and make significant investments, leading to market growth.

The Latin American bladder cancer therapeutics market is expected to rise at a CAGR of 5.18% from 2022 to 202.

The bladder cancer therapeutics market in the Middle East and Africa is forecasted to value USD 30.55 million by 2027.

KEY MARKET PLAYERS:

Companies leading the Global Bladder Cancer Therapeutics Market profiled in the report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland) and Celgene Corporation (U.S.)

RECENT MARKET DEVELOPMENTS:

• On January 07, 2020, Pfizer and Merck KGaA jointly announced that U.S. FDA approved PD-L1 inhibitor Bavencio. Also, they stated that this is evaluating positive data from the interim analysis of a phase-III study and soon going to show better results in patients suffering from advanced/metastatic urothelial carcinoma, a form of bladder cancer.